The best-selling drug in the world is no longer a tablet. The pipeline behind it is no longer led by small molecules. The single most tablet-dependent pharmaceutical company of 2001 has spent the last twenty-five years replacing those tablets — and when it had $43 billion to deploy in 2023, it spent it on biologics. The transition has already happened.
The numbers below are not a forecast. They are the present, hiding in plain sight — assembled from FDA filings, Pfizer’s quarterly accounts, IQVIA’s pipeline analysis, and the launch sheets of the companies that have made the largest M&A decisions of the modern pharmaceutical era.
By Ibumix · 12-minute read
1. The headline that ought to be a headline
The compressed pharmaceutical tablet is the most-produced manufactured object in human history. Several trillion are made each year. For close to two centuries the tablet has been so completely the default of oral medicine that the words “drug” and “pill” are used interchangeably in every language pharma operates in.
That interchangeability is now out of date.
The best-selling drug on the planet in 2024 was Keytruda. It generated $29.5 billion in global sales — close to half of Merck’s entire revenue. It is not a tablet. It is a monoclonal antibody, delivered by intravenous infusion in a clinic over thirty minutes.
Twenty-three years earlier, the best-selling drug on the planet was Lipitor — a small white tablet of atorvastatin, taken once a day with water. Every single drug in the global top ten of 2001 was a tablet: Lipitor, Prilosec, Prevacid, Zocor, Celebrex, Zoloft, Paxil, Vioxx, Prozac, Augmentin. In 2024, the majority of the global top ten are biologics or injectables. Two of them — Ozempic and Mounjaro — barely existed as a commercial category five years ago.
In a single working lifetime, the dominant format of medicine has flipped. The industry’s vocabulary has not.
2. Five facts that close the argument
Each of the five points below is sourced. Each is drawn from a recognised authority — Merck’s filings, the FDA register, IQVIA’s pipeline analysis, Grand View Research, the trade press. Read together, they do not describe a future. They describe what has already happened.
First. The world’s top-selling drug is an infused biologic, not a tablet. Keytruda’s $29.5 billion in 2024 sales is larger than the combined peak revenue of Lipitor, Plavix and Crestor at their height. The single most lucrative position in pharma is now held by a format that cannot be compressed into a die.
Second. In 2001, every drug in the global top ten was a tablet. In 2024, the majority are biologics or injectables — Keytruda, Dupixent, Ozempic, Skyrizi, Opdivo, Mounjaro, Stelara — outnumbering the tablets (Biktarvy, Eliquis, Rinvoq) by a clear margin. The lay phrase “the world’s top medicines” no longer reliably means “tablets”.
Third. The GLP-1 receptor agonist market — Ozempic, Wegovy, Mounjaro, Zepbound — is forecast to reach $157 billion by 2030, growing at roughly 17% a year. Ninety-three percent of that volume in 2024 was delivered by injection.
Fourth. One in three of the FDA’s novel drug approvals in 2024 was a biologic — sixteen of fifty CDER approvals. The small-molecule share of FDA approvals, which averaged about three-quarters for most of the 2010s, has now stabilised around two-thirds. Even within that two-thirds, a growing portion are peptides, oligonucleotides and other modalities the compressed tablet is a poor fit for.
Fifth. Biologic revenue is forecast to overtake innovative small-molecule revenue inside the next five years. Projections from EvaluatePharma, IQVIA and Pharmaceutical Technology converge on biologics accounting for roughly 55% of innovative drug sales by 2027.
Table A. The world’s top ten, 2001 vs 2024
| Rank | Top 10 of 2001 | Route | Top 10 of 2024 | Route |
|---|---|---|---|---|
| 1 | Lipitor | Oral tablet | Keytruda | IV infusion |
| 2 | Prilosec | Oral capsule | Ozempic | SC injection |
| 3 | Prevacid | Oral capsule | Dupixent | SC injection |
| 4 | Zocor | Oral tablet | Eliquis | Oral tablet |
| 5 | Celebrex | Oral capsule | Biktarvy | Oral tablet |
| 6 | Zoloft | Oral tablet | Skyrizi | SC injection |
| 7 | Paxil | Oral tablet | Opdivo | IV infusion |
| 8 | Vioxx | Oral tablet | Mounjaro | SC injection |
| 9 | Prozac | Oral capsule | Stelara | SC injection |
| 10 | Augmentin | Oral tablet | Rinvoq | Oral tablet |
| 10 of 10 oral solid | 100% tablet/capsule | 3 of 10 oral solid — 7 of 10 injectable/IV | ||
Sources: Drug Topics, Top 200 brand and generic drugs by retail sales 2001 (US retail, used as proxy for global lead); BioSpace, 10 Best-Selling Drugs of 2024 (global). Routes verified against FDA prescribing information for each product.
3. A historic case: Pfizer is the test of the thesis
Macro statistics are easy to dismiss. The clearer test of an industry-level claim is to put it against a single, named, publicly traded incumbent and ask whether the claim survives the corporate accounts. Pfizer is the cleanest possible candidate. No major pharmaceutical company has been more identified with the tablet than Pfizer was at the turn of the century.
In 2001, Pfizer reported eight human-pharma products with sales of more than one billion dollars each: Lipitor, Norvasc, Zoloft, Neurontin, Celebrex, Zithromax, Viagra and Diflucan. Together they accounted for 76% of human-pharma revenue. Every single one was a tablet or capsule. If a company embodied the tablet era, it was Pfizer 2001.
Twenty-five years later, every drug on that list has gone off patent — Lipitor in 2011, Viagra in 2017, Celebrex in 2014, Zithromax in 2005, Zoloft in 2006, Norvasc in 2007, Neurontin in 2004, Diflucan in 2004. Pfizer has had to rebuild the company around an entirely new portfolio. Where it has rebuilt is the data point.
In the first quarter of 2026, Pfizer reported $14.45 billion of revenue. Eliquis, an oral anticoagulant co-promoted with Bristol Myers Squibb, held the top position at $2.16 billion, up 13%. That is the surviving tablet at the top, and this piece says so plainly. Tablets are not gone.
The story is what sits behind Eliquis. The Vyndaqel family — capsules for transthyretin amyloidosis, a rare disease — turned over $1.6 billion, growing on international expansion rather than mass-market scale. Ibrance ($1.0 billion, a specialty oncology capsule) declined 1%. The growth in the rest of the portfolio came from formats that are not tablets: Padcev, an intravenous antibody-drug conjugate; Abrysvo, an injectable RSV vaccine, up 31% to $180 million; Comirnaty, the BioNTech-partnered injectable mRNA COVID vaccine; the Prevnar pneumococcal vaccine franchise.
The most revealing decision is the M&A budget. In March 2023 Pfizer agreed to acquire Seagen for $43 billion — the largest single acquisition in company history. Seagen’s portfolio is biologics: Padcev, Tukysa, Adcetris, Tivdak. Antibody-drug conjugates, infused or injected. When Pfizer — the company most associated with the tablet era — had the largest cheque of its life to write to replace the portfolio that built it, it did not buy a tablet pipeline. It bought biologics.
The clearest evidence that the tablet era is ending is not what the start-ups are doing. It is what the incumbents are buying.
Table B. Pfizer 2001 vs Pfizer Q1 2026
| Pfizer 2001 · >$1B human-pharma assets | Route | Pfizer Q1 2026 · Top revenue contributors | Route |
|---|---|---|---|
| Lipitor | Oral tablet | Eliquis (with BMS) — $2.16B | Oral tablet |
| Norvasc | Oral tablet | Vyndaqel family — $1.6B | Oral capsule |
| Zoloft | Oral tablet | Ibrance — $1.0B | Oral capsule |
| Neurontin | Oral capsule | Comirnaty | IM vaccine |
| Celebrex | Oral capsule | Prevnar family | IM vaccine |
| Zithromax | Oral tablet | Padcev (ex-Seagen) | IV biologic |
| Viagra | Oral tablet | Abrysvo — +31% | IM vaccine |
| Diflucan | Oral tablet | Paxlovid | Oral tablet |
| 8 of 8 oral solid · 76% of human pharma revenue | 100% tablet/capsule | Largest acquisition since: Seagen, $43B (Mar 2023). Portfolio: biologics. | |
Sources: Pfizer Annual Report 2001 (Form 10-K); Pfizer Q1 2026 Earnings Release (SEC Form 8-K, 5 May 2026); Pfizer-Seagen acquisition announcement, 13 March 2023. Q1 2026 row ordered by strategic relevance to the article’s argument, not by absolute revenue.
4. Where the pipeline has already decided the next decade
Financial league tables are lagging indicators. They report what worked five and ten years ago. The leading indicator — the one that decides what the league table looks like in 2030 — is the clinical pipeline, and in particular what is starting in Phase II.
That number has now crossed a threshold no-one inside the industry advertises and almost no-one outside it notices.
According to IQVIA’s Global Trends in R&D 2025 report, small molecules accounted for 62% of Phase II clinical trial starts in 2015. By 2024 that figure had fallen to 47%. At Phase III the same decline runs from 65% to 53%. For the first time in pharma’s modern history, the format the compressed tablet is built around — a small, stable, orally absorbable chemical entity — is a minority of what is moving through development.
The pipeline that will fill the FDA’s approval calendar for the second half of the 2020s is already, by majority, not made of small molecules.
This is the quiet, decisive fact. Earlier moments of “the tablet is dying” commentary were calls about preference. This one is about composition. The future of approvals is being shaped today in trials that were designed two and three years ago. They are not, on the whole, designs that resolve into a compressed solid.
5. Why “the tablet is dying” turned out to be true this time
Versions of this claim have circulated for thirty years. What is different now is that three forces have arrived at the same point at the same time, and they reinforce each other.
The first is the molecule. The new wave of drugs — monoclonal antibodies, GLP-1 peptides, bispecifics, oligonucleotides, mRNA vaccines, cell and gene therapies — are physically too large, too fragile, or too soluble in the wrong direction to survive a compressed-tablet route to the bloodstream. The compressed tablet was designed for small, stable, orally absorbable molecules. The molecules that are now winning are not those molecules.
The second is the patient. Roughly one adult in six reports difficulty swallowing; in patients over seventy that figure rises towards 40%. The fastest-growing populations in pharma — ageing patients in developed markets, paediatric populations in developing ones — are the ones least well served by a swallowed solid. Injectables, patches, liquids and depot formulations are not a quirky alternative for this group. They are the only formats that meet the demographic.
The third is the economics. The most lucrative therapy areas of the next decade — oncology, immunology, metabolic disease, rare disease — are dominated by molecules that do not arrive as tablets. The single largest commercial category to have emerged in the last five years is GLP-1 for obesity and diabetes, and it is overwhelmingly injectable. Capital flows have followed: venture funding, big-pharma M&A and CDMO investment have all rotated decisively towards non-tablet formats.
Any one of these three forces in isolation would not be enough. The tablet has weathered worse on its own. The reason this transition is real is that the molecule, the patient and the money are now pointing in the same direction at the same time.
6. Every industry has a legacy format
This pattern is not unique to medicine. Every mature industry has a legacy format — the one that defined it for a century, then was replaced by the demands of the next century.
- Film cameras gave way to digital sensors when the demands of speed, scale and editability outgrew silver halide.
- Cash gave way to digital payments when the demands of distance, settlement speed and traceability outgrew physical currency.
- DVDs gave way to streaming when the demands of catalogue size, distribution cost and on-demand availability outgrew the disc.
- Magnetic tape gave way to solid-state storage when density, access time and durability outgrew it.
- Combustion engines are giving way to electric drivetrains for the same family of reasons.
Each legacy format earned its place. Each was, in its own moment, the best available answer to a real engineering problem. None failed because of negligence; all were displaced because the constraints that defined them stopped being the constraints that mattered. The compressed tablet sits in the same category. It is not a poor format. It is a format whose constraint set has been overtaken.
Legacy formats do not get replaced because they are bad. They get replaced because the question they were answering has stopped being the question that matters.
7. But isn’t the oral GLP-1 race the opposite story?
The strongest objection any informed reader can raise to this article is the oral GLP-1 race. Pharma’s largest current programmes are not racing to invent the next injectable — they are racing to put injectable peptides back into a tablet. Novo Nordisk’s Rybelsus, approved in 2019, is oral semaglutide: the same molecule as Ozempic, in a pill. Oral Wegovy, approved in January 2026, took roughly a third of new-to-brand GLP-1 prescriptions within eight weeks of launch. Eli Lilly’s orforglipron, a small-molecule oral GLP-1, is in Phase III with positive readouts. If a tablet for the most important drug class of the decade is the active research direction, in what sense is the tablet ending?
The objection is precise. The answer is sharper than it looks.
Rybelsus is not a tablet in the sense that Lipitor was a tablet. The peptide it carries cannot survive the stomach unassisted. Bioavailability is approximately 0.4 to 1 per cent. To get any drug into the bloodstream at all, the formulation co-delivers SNAC — sodium N-(8-[2-hydroxybenzoyl]amino)caprylate — a permeation enhancer that briefly opens a window in the stomach lining. The resulting oral dose is 7 to 14 milligrams, against Ozempic’s sub-milligram weekly injection. The object is an oral solid. The engineering is delivery science.
Rybelsus shares a shape with Lipitor. It does not share an engineering philosophy. The compressed tablet of 1843 was a manufacturing convenience. Rybelsus is an engineered delivery vehicle that happens to dissolve in the gut.
Orforglipron and the other oral small-molecule GLP-1 programmes go further. They are designed from the molecule outward — small enough and stable enough to survive the gut without a permeation enhancer at all. They are not the rescue of the tablet. They are the rescue of the oral route, and they only exist because the medicinal-chemistry effort required to design a small molecule that mimics a peptide is now considered worth that effort. Pfizer’s danuglipron — discontinued in late 2025 after a liver signal in Phase II — is a reminder that the work is hard. The category exists because oral delivery is valuable. It does not exist because the compressed solid is back.
The honest framing is this. The injectable GLP-1 launches of 2017 to 2023 are not the start of an injectable era and the oral GLP-1 launches of 2019 to 2027 are not its reversal. They are two ends of the same transition. The format that is dying is not “the oral route”. The format that is dying is the compressed solid as the unmarked default — the route every new molecule begins from, and only departs from when forced. What replaces it is a portfolio of routes, oral included, in which the choice of delivery is a deliberate engineering decision made for that molecule, that patient, that disease. The tablet survives where it earns its place. It no longer wins by default.
8. What replaces it
“The end of the tablet” should not be read as the rise of a single successor. The defining feature of the next era of medicine is that the format is chosen to fit the molecule and the patient, rather than the molecule and the patient being forced to fit the format.
In practice, that resolves into a small family of delivery routes, each carrying the share of the pipeline that suits it:
- Subcutaneous and intravenous biologics, where the molecule is a large protein and the patient is willing to inject or be infused — already the dominant format for oncology and immunology.
- Peptide injectables, where the molecule is a regulatory hormone analogue requiring rapid onset and tight dosing control — the format of the GLP-1 wave.
- Engineered oral peptide systems (Rybelsus, oral Wegovy and successors), where the molecule is too fragile for an unassisted tablet but the patient route demands oral.
- Small-molecule oral mimics of peptide biology (orforglipron and successors), where the molecule itself has been redesigned to make the oral route viable without a permeation enhancer.
- Depot and long-acting injectables, where adherence matters more than convenience — increasingly used in psychiatry, HIV and contraception.
- Transdermal and patch delivery, where steady plasma levels matter more than peak dosing — already standard for hormone replacement and nicotine.
- Liquid and lipid-based oral systems, where oral delivery still matters but the molecule is too poorly soluble, too rapidly metabolised or too variably absorbed for compression to be the right route — the territory Ibumix works in.
None of these routes is new. What is new is that, taken together, they are no longer the exception. They are the centre of gravity of the next decade of medicine — and the compressed tablet is one route on that menu, not the menu itself.
One honest caveat. The transition described above is most visible in developed-market sales and FDA pipeline data. In low- and middle-income markets, where the constraints of cost, cold chain and infrastructure remain decisive, the compressed tablet will hold its dominance for longer — but it will hold it as the older format, not as the default of the next era. That is a different argument, not a contradiction of this one.
9. The orientation that follows
For most of the last fifty years, the heroic act in pharma was discovery — the molecule. Delivery was a step at the end of the process, handled by a different department, valued at a fraction of the price of the chemistry that preceded it. The compressed tablet was the unmarked default of that orientation: medicine reduced to a die.
The heroic act of the next fifty years is delivery. The molecule has become cheaper to find, easier to model and harder to differentiate. The differentiation now lies in how the molecule reaches the patient — and in the formats that exist downstream of “a small, stable, orally absorbable solid”. That is where the value, the patent territory and the clinical surprise of the next decade will sit.
This is not the end of the tablet as an object. Aspirin will still be sold in blister packs in 2040. The world has too much sunk cost in the format for it to disappear. What is ending is the assumption that the tablet is the default — the unmarked answer that every new molecule starts from and only departs from under pressure. That assumption is what the data above retires.
The question is no longer whether the tablet era ends. It is what replaces it — and who leads that shift.
Ibumix is built at exactly that point. The company’s work is not to make a better pill. It is to take the routes the next decade of medicine actually needs — liquid and lipid-based oral delivery, designed for absorption and consistency from the first sketch — and put them on the same scale, the same regulatory footing and the same supply chain as the format they are replacing.
The next era of medicine will not be defined by which molecule was discovered. It will be defined by how that molecule reached the body. The tablet was the answer to the wrong half of the question, for far too long.
Sources
- Merck & Co. FY2024 Earnings Release (SEC Form 8-K). sec.gov
- BioSpace — 10 Best-Selling Drugs of 2024. biospace.com
- Drug & Device World — Top 10 highest-grossing drugs in 2024. druganddeviceworld.com
- Drug Topics — Top 200 brand and generic drugs by retail sales, 2001. drugtopics.com
- Pfizer FY2001 Annual Report (Form 10-K). sec.gov
- Pfizer Q1 2026 Earnings Release (SEC Form 8-K), 5 May 2026. sec.gov
- Pfizer / Seagen acquisition announcement, 13 March 2023. pfizer.com
- IQVIA Institute — Global Trends in R&D 2025. iqvia.com
- PMC — The Pharmaceutical Industry in 2024: An Analysis of FDA Drug Approvals. ncbi.nlm.nih.gov
- Pharmaceutical Technology — Biologic sales forecast to pass innovative small-molecule sales. pharmaceutical-technology.com
- Grand View Research — GLP-1 Weight-Loss Drugs Market Size Report, 2030. grandviewresearch.com
- PMC — Prevalence and Characteristics of Dysphagia. pmc.ncbi.nlm.nih.gov
- Ibumix — companion pieces: Bioavailability Is Pharma’s Dirty Secret; The 80% Problem; Pharma Optimised for Factories, Not Humans; Beyond Dissolution. ibumix.com/blog
Part of the Ibumix series on the tablet’s limits. See also: Pharma Optimised for Factories, Not Humans and Standard Dosing Is Fundamentally Broken.